STAA Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
STAAR Surgical Company 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$32.79 |
| 52주 최고가 | US$35.87 |
| 52주 최저가 | US$15.59 |
| 베타 | 1.2 |
| 1개월 변동 | 31.58% |
| 3개월 변동 | 84.63% |
| 1년 변동 | 74.69% |
| 3년 변동 | -44.72% |
| 5년 변동 | -77.12% |
| IPO 이후 변동 | 38.06% |
최근 뉴스 및 업데이트
Seeking Alpha • May 16
STAAR Surgical Q1 2026: Early Signs Of A Durable Turnaround
Summary STAAR Surgical Company delivered a robust 1Q26 beat, with revenue up 119% YoY to $93.5M and a swing to $5.2M net income. China’s market rebound, normalized inventory, and rapid EVO+ ICL adoption drove topline strength, while disciplined OpEx and manufacturing efficiency boosted margins to 73.6%. STAA is benefiting from a structural shift toward lens-based refractive surgery, gaining U.S. share despite a shrinking laser market and expanding its addressable market via FDA approval. Valuation remains elevated at 4.4x forward sales and 57x forward P/E, requiring sustained high-teens revenue growth and margin expansion to justify current multiples. Read the full article on Seeking Alpha
내러티브 업데이트 • May 15
STAA: Limited China Visibility And Missing Guidance Will Restrain Future Share Performance
Analysts have raised the fair value estimate for STAAR Surgical stock from $13.00 to $16.00, citing higher price targets supported by stronger Q1 results, improving confidence in a China rebound, and updated models that reflect better profitability assumptions and a lower future P/E multiple. Analyst Commentary Street research on STAAR Surgical has turned more constructive around the recent Q1 update, but the tone is not uniformly positive.Recent updates
Seeking Alpha • May 16
STAAR Surgical Q1 2026: Early Signs Of A Durable Turnaround
Summary STAAR Surgical Company delivered a robust 1Q26 beat, with revenue up 119% YoY to $93.5M and a swing to $5.2M net income. China’s market rebound, normalized inventory, and rapid EVO+ ICL adoption drove topline strength, while disciplined OpEx and manufacturing efficiency boosted margins to 73.6%. STAA is benefiting from a structural shift toward lens-based refractive surgery, gaining U.S. share despite a shrinking laser market and expanding its addressable market via FDA approval. Valuation remains elevated at 4.4x forward sales and 57x forward P/E, requiring sustained high-teens revenue growth and margin expansion to justify current multiples. Read the full article on Seeking Alpha내러티브 업데이트 • May 15
STAA: Limited China Visibility And Missing Guidance Will Restrain Future Share Performance
Analysts have raised the fair value estimate for STAAR Surgical stock from $13.00 to $16.00, citing higher price targets supported by stronger Q1 results, improving confidence in a China rebound, and updated models that reflect better profitability assumptions and a lower future P/E multiple. Analyst Commentary Street research on STAAR Surgical has turned more constructive around the recent Q1 update, but the tone is not uniformly positive.
내러티브 업데이트 • Apr 20
STAA: China Uncertainty And Leadership Transition Will Drive Bearish Reassessment
STAAR Surgical's updated fair value estimate shifts from $26.56 to $21.11 as analysts factor in revised Street targets. These include recent cuts to around $18 to $22 that reflect questions on China exposure and mixed near term visibility, despite some more supportive views emerging.
내러티브 업데이트 • Apr 06
STAA: China Clarity And Post Alcon Reset Will Drive Future Re Rating
Analysts have trimmed price targets on STAAR Surgical to a range around $18 to $22, with a consensus reset of approximately $23.00, reflecting ongoing questions about China exposure, recent Q4 volatility, and limited near term visibility following the rejected Alcon deal. Analyst Commentary Recent Street commentary around STAAR Surgical centers on uncertainty, but there are pockets of optimism that readers should weigh alongside the more cautious views.내러티브 업데이트 • Mar 23
STAA: Ongoing China Uncertainty And Governance Turmoil Will Pressure Shares
Analysts have reduced the consolidated price target for STAAR Surgical to $22 from $28, reflecting lower assumptions for revenue growth and profit margins, a much higher future P/E multiple, and ongoing uncertainty around China and the company’s broader path forward. Analyst Commentary Recent Street research on STAAR Surgical points to a cautious tone, with multiple bearish analysts cutting price targets and reiterating neutral or underweight stances.내러티브 업데이트 • Mar 09
STAA: China Clarity And Post Alcon Reset Will Shape Future Upside Potential
Narrative Update on STAAR Surgical Our analyst price target for STAAR Surgical has been revised from $30.75 to $23.00 as analysts factor in recent target cuts, ongoing uncertainty around China and limited near term visibility highlighted in the latest research. Analyst Commentary Recent research on STAAR Surgical has leaned cautious, with multiple firms revising price targets lower and emphasizing uncertainty around the company’s outlook, particularly related to China and the failed Alcon transaction.내러티브 업데이트 • Feb 23
STAA: Post Deal Rejection Concerns Will Keep Shares Under Pressure
Analysts have reduced their average price targets on STAAR Surgical by high single digit dollar amounts to around $13.00. This reflects more cautious views on profit margins and valuation multiples after the failed Alcon deal and a series of Neutral and Underweight ratings.내러티브 업데이트 • Feb 08
STAA: Post Deal Collapse Uncertainty Will Pressure Shares Until Leadership Path Clears
Narrative Update on STAAR Surgical The analyst price target for STAAR Surgical has been reduced by US$8.75 following a neutral initiation, an Underweight resumption, and cautious commentary from several firms who highlight limited investor appetite until there is greater clarity on the company after the failed Alcon transaction. Analyst Commentary Recent Street research around STAAR Surgical has leaned cautious, with several firms highlighting valuation, execution, and growth risks following the failed Alcon transaction and the subsequent shareholder vote.내러티브 업데이트 • Jan 25
STAA: Post Alcon Deal Collapse And CEO Exit Will Cap Near Term Upside
Analysts have trimmed their fair value estimate for STAAR Surgical from US$17.41 to US$13.00, reflecting lower assumed revenue growth and a reduced future P/E multiple, alongside cautious commentary around limited buyer interest and uncertainty following the failed Alcon deal. Analyst Commentary Recent Street research has tilted clearly cautious, with several bearish analysts highlighting valuation pressure, deal uncertainty, and limited near term visibility on the business.내러티브 업데이트 • Jan 10
STAA: Failed Alcon Deal And Takeover Optionality Will Reshape Future Appeal
Analysts have lifted their fair value estimate for STAAR Surgical shares from US$28.00 to US$30.75, reflecting updated assumptions on growth, margins and future P/E multiples after recent debate over the failed Alcon deal and the limited near term appeal highlighted in recent research. Analyst Commentary Recent research has centered on the failed Alcon transaction, shareholder pushback on deal terms, and the limited near term appeal cited by several firms.내러티브 업데이트 • Dec 26
STAA: Amended Alcon Deal And Activist Push Will Drive Bullish Upside
Analysts have nudged their fair value estimate for STAAR Surgical higher from approximately $25.88 to $26.56. This reflects modestly stronger growth and margin expectations while acknowledging that any amended Alcon deal is unlikely to include a materially higher bid.내러티브 업데이트 • Dec 12
STAA: Merger Uncertainty Will Restrain Upside Despite Higher All-Cash Offer
Analysts have modestly raised their price target on STAAR Surgical from $16.00 to approximately $17.41 per share, citing slightly improved assumptions for long term revenue growth, profitability, and future valuation multiples, while they continue to monitor ongoing merger term discussions with Alcon. Analyst Commentary Bearish analysts highlight that the postponed shareholder meeting reinforces uncertainty around the timing and ultimate outcome of the proposed acquisition, which in turn clouds visibility on STAAR Surgical's standalone valuation.내러티브 업데이트 • Nov 28
STAA: Amended Merger Terms And Shareholder Opposition Will Guide Share Price Direction
Analysts have maintained their price target for STAAR Surgical at $25.88, citing limited expected upside due to ongoing merger negotiations and continued uncertainty regarding the acquisition terms. Analyst Commentary Market commentary surrounding STAAR Surgical’s ongoing merger negotiations reflects mixed analyst sentiment, with both cautious and optimistic perspectives regarding the company’s prospects and valuation.내러티브 업데이트 • Nov 12
STAA: Merger Discussions and Shareholder Opposition Will Shape Path Forward
Analysts have revised STAAR Surgical's price target downward to $16 from previous levels. They cite ongoing shareholder opposition to the proposed merger terms and uncertainty about a potential acquisition price.내러티브 업데이트 • Oct 29
Board Opposition And Postponed Vote Will Shape Acquisition Outcome In 2025
Analysts have raised their average price target for STAAR Surgical from $20 to $28 per share. They cite the strategic rationale and valuation of the proposed acquisition by Alcon as key drivers for the upward revision.내러티브 업데이트 • Oct 15
Introduction Of EVO+ Will Open Market Opportunities In 2025
Analysts have raised their price target for STAAR Surgical from $24.63 to $25.88. This reflects the impact of an increased acquisition offer and the perceived strategic value from Alcon's proposed purchase.내러티브 업데이트 • Aug 20
Introduction Of EVO+ Will Open Market Opportunities In 2025
Analysts have raised their price targets for STAAR Surgical primarily to reflect the proposed $28/share acquisition by Alcon, which sets a new benchmark valuation and limits further upside, resulting in a new consensus fair value of $24.14. Analyst Commentary Bullish analysts raised their price targets to align with the proposed $28/share acquisition price by Alcon.내러티브 업데이트 • Aug 06
Introduction Of EVO+ Will Open Market Opportunities In 2025
Driven by a significant improvement in net profit margin despite a higher discount rate, STAAR Surgical's consensus price target has increased from $19.20 to $22.11. What's in the News Alcon Inc.분석 기사 • Jul 04
Getting In Cheap On STAAR Surgical Company (NASDAQ:STAA) Might Be Difficult
There wouldn't be many who think STAAR Surgical Company's ( NASDAQ:STAA ) price-to-sales (or "P/S") ratio of 3.2x is...분석 기사 • Apr 05
Is STAAR Surgical Company (NASDAQ:STAA) Trading At A 37% Discount?
Key Insights The projected fair value for STAAR Surgical is US$25.07 based on 2 Stage Free Cash Flow to Equity Current...분석 기사 • Feb 14
Why Investors Shouldn't Be Surprised By STAAR Surgical Company's (NASDAQ:STAA) 26% Share Price Plunge
Unfortunately for some shareholders, the STAAR Surgical Company ( NASDAQ:STAA ) share price has dived 26% in the last...Seeking Alpha • Feb 12
STAAR Surgical Q4: Ongoing Challenges In China Masks Healthy Growth Elsewhere
Summary STAAR Surgical's Q4 results were severely impacted by lower demand and high inventory levels in China. Global growth ex-China was 17% in Q4 and is expected to remain strong at 12% for FY25, with US growth of close to 15%. Cash burn is expected to be significant, but the company is financially healthy, having $232 million in cash and no debt on its balance sheet. Following the post-earnings drop, shares are cheaply valued given the long growth runway ahead, which leads me to maintain my Buy rating on STAA stock. Read the full article on Seeking AlphaSeeking Alpha • Jan 31
STAAR Surgical: Growth Story Remains Intact Despite Some Challenges
Summary Shares have been under pressure lately due to weak demand from China, which is by far the company’s largest market. The market opportunity in the US remains large, and management is investing heavily to tap into it. I have modest expectations for overall growth in FY25 of 9%, with markets excluding China growing significantly faster. The FCF margin in FY25 is expected to be around 8.3% given the ongoing growth investments, while I expect that it can reach close to 20% in the long term. I am assigning a Buy rating on the stock with a target priceof $35, implying an upside of over 45%. Read the full article on Seeking Alpha분석 기사 • Nov 29
STAAR Surgical Company's (NASDAQ:STAA) Earnings Haven't Escaped The Attention Of Investors
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 19x, you may...분석 기사 • Oct 24
Return Trends At STAAR Surgical (NASDAQ:STAA) Aren't Appealing
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...
새로운 내러티브 • Sep 13
EVO ICL Technology Transforms Vision Care, Securing Major Growth And Market Share Expansion
STAAR Surgical's record sales and expansion in the diopter curve indicate strong global adoption of EVO ICL technology and potential for increased market share.Seeking Alpha • Sep 05
STAAR Surgical: Expecting A Re-Acceleration In Growth As Investments Materialize
Summary STAAR Surgical shares are down more than 15% since Q2 earnings, despite management raising full-year revenue guidance. Investments in the US market appear to be yielding promising results, as sales were up 25% year over year. According to my estimates, the company is on track to meet the low end of its 2026 financial targets. I have a price target of $46 by 2026, which represents an attractive upside from today’s level. Read the full article on Seeking Alpha분석 기사 • Aug 10
Results: STAAR Surgical Company Exceeded Expectations And The Consensus Has Updated Its Estimates
STAAR Surgical Company ( NASDAQ:STAA ) investors will be delighted, with the company turning in some strong numbers...분석 기사 • Aug 05
STAAR Surgical Company's (NASDAQ:STAA) Popularity With Investors Is Clear
When close to half the companies in the Medical Equipment industry in the United States have price-to-sales ratios (or...분석 기사 • Jul 12
The Returns At STAAR Surgical (NASDAQ:STAA) Aren't Growing
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...분석 기사 • May 27
Is There Now An Opportunity In STAAR Surgical Company (NASDAQ:STAA)?
While STAAR Surgical Company ( NASDAQ:STAA ) might not have the largest market cap around , it received a lot of...분석 기사 • Apr 26
Market Participants Recognise STAAR Surgical Company's (NASDAQ:STAA) Revenues Pushing Shares 30% Higher
Despite an already strong run, STAAR Surgical Company ( NASDAQ:STAA ) shares have been powering on, with a gain of 30...주주 수익률
| STAA | US Medical Equipment | US 시장 | |
|---|---|---|---|
| 7D | 2.4% | 3.0% | -0.8% |
| 1Y | 74.7% | -18.3% | 27.1% |
수익률 대 산업: STAA은 지난 1년 동안 -18.3%의 수익을 기록한 US Medical Equipment 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: STAA은 지난 1년 동안 27.1%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| STAA volatility | |
|---|---|
| STAA Average Weekly Movement | 9.2% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: STAA는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: STAA의 주간 변동성(9%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1982 | 921 | Deborah Andrews | www.staar.com |
스타 서지컬 컴퍼니는 자회사와 함께 안구용 인공수정체와 렌즈를 눈에 전달하는 액세서리 전달 시스템을 설계, 개발, 제조, 판매하고 있습니다. 이 회사는 근시, 원시, 난시, 노안 등 시각 장애 치료를 위한 굴절 수술에 사용되는 EVO ICL, EVO+ ICL, EVO Visian ICL, EVO Viva ICL로 구성된 이식형 콜라머 렌즈 제품군(ICL)을 제공합니다. 안과 전문의뿐만 아니라 안과 외과의, 시력 및 수술 센터, 병원, 정부 시설, 유통업체 등 의료 서비스 제공자에게 서비스를 제공합니다.
STAAR Surgical Company 기초 지표 요약
| STAA 기초 통계 | |
|---|---|
| 시가총액 | US$1.65b |
| 순이익 (TTM) | -US$21.03m |
| 매출 (TTM) | US$290.38m |
5.6x
주가매출비율(P/S)-77.6x
주가수익비율(P/E)STAA는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| STAA 손익계산서 (TTM) | |
|---|---|
| 매출 | US$290.38m |
| 매출원가 | US$67.10m |
| 총이익 | US$223.27m |
| 기타 비용 | US$244.31m |
| 순이익 | -US$21.03m |
최근 보고된 실적
Apr 03, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -0.42 |
| 총이익률 | 76.89% |
| 순이익률 | -7.24% |
| 부채/자본 비율 | 0% |
STAA의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/21 10:55 |
| 종가 | 2026/05/21 00:00 |
| 수익 | 2026/04/03 |
| 연간 수익 | 2026/01/02 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
STAAR Surgical Company는 21명의 분석가가 다루고 있습니다. 이 중 11명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Michael Gorman | BTIG |
| William Plovanic | Canaccord Genuity |
| John Young | Canaccord Genuity |